沉默信息调节因子1在肿瘤发生发展中的作用

doi:0.3760/cma.j.issn.1673-422X.2013.12.007

摘要/Abstract

摘要： 沉默信息调节因子1（SIRT1）是一种依赖于烟酰胺腺嘌呤二核苷酸的组蛋白脱乙酰酶，参与肿瘤的发生发展过程。研究表明，SIRT1在胃癌、乳腺癌、前列腺癌等多种实体肿瘤中呈高表达，可促进肿瘤发生发展；同时发现，SIRT1在其他肿瘤如胶质母细胞瘤、膀胱癌、卵巢癌等中SIRT1表达降低，起抑癌基因的作用。因此，SIRT1的具体作用机制仍未阐明，尚存争议。

关键词: 肿瘤, 沉默信息调节因子1

Abstract: Silent information regulator 1 (SIRT1) is a kind of histone deacetylase which dependents on nicotinamide adenine dinucleotide. It is involved in the occurrence and development of tumors. Data show that SIRT1 is highly expressed in many tumors, such as gastric cancer, breast cancer, prostate cancer and so on. On the other hand, the expression of SIRT1 is lower in many other types of tumors, including glioblastomas, bladder cancer, ovarian cancer and so on. Therefore, the role of SIRT1 in tumor formation process is still uncertain and controversial.

Key words: Neoplasms, Silent information regulator 1

傅德强, 吴文艺, 张丽婷. 沉默信息调节因子1在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2013, 40(12): 902-904.

FU De-Qiang, WU Wen-Yi, ZHANG Li-Ting. Roles of SIRT1 in tumorigenesis and tumor progression[J]. Journal of International Oncology, 2013, 40(12): 902-904.

参考文献

［1］ Dirks AJ, Leeuwenhburgh C. Tumor necrosis factor alpha signaling in skeletal muscle: effects of age and caloric restriction. J Nutr Biochem, 2006, 17(8): 501508. ［2］ Cha EJ, Noh SJ, Kwon KS, et al. Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res, 2009, 15(13): 44534459. ［3］ Jung W, Hong KD, Jung WY, et al. SIRT1 expression is associated with good prognosis in colorectal cancer. Korean J Pathol, 2013, 47(4): 332339. ［4］ Stenzinger A, Endris V, Klauschen F, et al. High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma. BMC Cancer, 2013, 13(1): 450. ［5］ Kuo SJ, Lin HY, Chien SY, et al. SIRT1 suppresses breast cancer growth through downregulation of the Bcl2 protein. Oncol Rep, 2013, 30(1): 125130. ［6］ Kriegl L, Vieth M, Kirchner T, et al. Upregulation of cMYC and SIRT1 expression correlates with malignant transformation in the serrated route to colorectal cancer. Oncotarget, 2012, 3(10): 11821193. ［7］ Hida Y, Kubo Y, Murao K, et al. Strong expression of a longevityrelated protein, SIRT1, in Bowen′s disease. Arch Dermatol Res, 2007, 299(2): 103106. ［8］ Vaziri H, Dessain SK, Ng Eaton E, et al. hSIR2 (SIRT1) functions as an NADdependent p53 deacetylase. Cell, 2001, 107(2): 149159. ［9］ Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell, 2001, 107(2): 137148. ［10］ Lain S, Hollick JJ, Campbell J, et al. Discovery, in vivo activity, and mechanism of action of a smallmolecule p53 activator. Cancer Cell, 2008, 13(5): 454463. ［11］ Rizki G, Iwata TN, Li J, et al. The evolutionarily conserved longevity determinants HCF1 and SIR2.1/SIRT1 collaborate to regulate DAF16/FOXO. PLoS Genet, 2011, 7(9): e1002235. ［12］ Dai JM, Wang ZY, Sun DC, et al. SIRT1 interacts with p73 and suppresses p73dependent transcriptional activity. J Cell Physiol, 2007, 210(1): 161166. ［13］ Wong S, Weber JD. Deacetylation of the retinoblastoma tumour suppressor protein by SIRT1. Biochem J, 2007, 407(3): 451460. ［14］ Pruitt K, Zinn RL, Ohm JE, et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet, 2006, 2(3): e40. ［15］ Cohen HY, Miller C, Bitterman KJ, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science, 2004, 305(5682): 390392. ［16］ Yuan Z, Zhang X, Sengupta N, et al. SIRT1 regulates the function of the Nijmegen breakage syndrome protein. Mol Cell, 2007, 27(1): 149162. ［17］ Li K, Casta A, Wang R, et al. Regulation of WRN protein cellular localization and enzymatic activities by SIRT1mediated deacetylation. J Biol Chem, 2008, 283(12): 75907598. ［18］ Deng CX. SIRT1, is it a tumor promoter or tumor suppressor?. Int J Biol Sci, 2009, 5(2): 147152. ［19］ Zhao W, Kruse JP, Tang Y, et al. Negative regulation of the deacetylase SIRT1 by DBC1. Nature, 2008, 451(7178): 587590. ［20］ Kim JE, Chen J, Lou Z. DBC1 is a negative regulator of SIRT1. Nature, 2008, 451(31): 583586. ［21］ Wang RH, Sengupta K, Li C, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell, 2008, 14(4): 312323. ［22］ Banks AS, Kon N, Knight C, et al. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab, 2008, 8(4): 333341. ［23］ Zhang QJ, Wang Z, Chen HZ, et al. Endotheliumspecific overexpression of class Ⅲ deacetylase SIRT1 decreases atherosclerosis in apolipoprotein Edeficient mice. Cardiovasc Res, 2008, 80(2): 191199. ［24］ Pfluger PT, Herranz D, VelascoMiguel S, et al. Sirt1 protects against highfat dietinduced metabolic damage. Proc Natl Acad Sci USA, 2008, 105(28): 97939798. ［25］郭淑芹, 朱春英, 张云良. SIRT1与肿瘤. 国际肿瘤学杂志, 2011, 38(8): 569572. ［26］ Firestein R, Blander G, Michan S, et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One, 2008, 3(4): e2020. ［27］ Wang RH, Zheng Y, Kim HS, et al. Interplay among BRCA1, SIRT1, and Survivin during BRCA1aggociated tumorigenesis. Mol Cell, 2008, 32(1): 1120. ［28］ Oberdoerffer P, Michan S, McVay M, et al. SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell, 2008, 135(5): 907918.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.